Therapies Targeting Stroke Recovery

被引:16
|
作者
Richard, Lorie G. [1 ]
Cramer, Steven C. [2 ,3 ]
机构
[1] Univ Utah, Dept Occupat & Recreat Therapies, Salt Lake City, UT USA
[2] Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza,Reed C239, Los Angeles, CA 90024 USA
[3] Calif Rehabil Inst, Los Angeles, CA USA
关键词
clinical trial; depression; phenotype; precision medicine; rehabilitation; stroke; therapeutics; ISCHEMIC-STROKE; REHABILITATION; DEPRESSION; STATEMENT; INJURY; CARE;
D O I
10.1161/STROKEAHA.122.041729
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke recovery therapeutics include many classes of intervention and numerous treatment targets. Stroke is a very heterogeneous disease. As such, stroke recovery therapeutics benefit from a personalized medicine approach that considers intersubject differences, such as in infarct location or stroke severity, when assigning treatment. Prediction of treatment responders can be improved by incorporating biological measures, such as neural injury and neural function, as the bedside behavioral phenotype has an incomplete relationship with the biological events underlying stroke recovery. Another ramification of high variability between patients is the need to examine effects of restorative therapies in relation to dose, time poststroke, and stroke severity in clinical trials. For example, enrollment across a wide time interval poststroke or in a population with a very broad range of deficits means high variance across patients in the biological state of the brain. The doses of rehabilitation therapy being studied are often low; it takes substantial practice to acquire a skill in the healthy brain; this is more, not less, pronounced after a stroke. Recognition and treatment of poststroke depression represents a major unmet need. These points are considered in the context of a review of recent advances in stroke recovery therapeutics.
引用
收藏
页码:265 / 269
页数:5
相关论文
共 50 条
  • [31] New therapies for stroke
    Caplan, LR
    ARCHIVES OF NEUROLOGY, 1997, 54 (10) : 1222 - 1224
  • [32] EMERGING STROKE THERAPIES
    GROTTA, JC
    SEMINARS IN NEUROLOGY, 1986, 6 (03) : 285 - 292
  • [33] Neuroprotective Therapies In Stroke
    Justin A. Zivin
    Drugs, 1997, 54 : 83 - 89
  • [34] Is Immunomodulation a Principal Mechanism Underlying How Cell-Based Therapies Enhance Stroke Recovery?
    Nikunj Satani
    Sean I. Savitz
    Neurotherapeutics, 2016, 13 : 775 - 782
  • [35] Developing a framework for utilizing adjunct rehabilitation therapies in motor recovery of upper extremity post stroke
    Teasell, Robert
    McIntyre, Amanda
    Viana, Ricardo
    Bateman, Emma A.
    Murie-Fernandez, Manuel
    Janzen, Shannon
    Saikaley, Marcus
    TOPICS IN STROKE REHABILITATION, 2023, 30 (05) : 493 - 500
  • [36] PERCEPTION ON USING ALTERNATIVE THERAPIES FOR STROKE RECOVERY AMONG HEALTH CARE PROFESSIONALS IN SRI LANKA
    Silva, S. N.
    Karunaratne, A.
    INTERNATIONAL JOURNAL OF STROKE, 2022, 17 (3_SUPPL) : 243 - 243
  • [37] Mechanisms of recovery in stroke patients with hemiparesis or aphasia: new insights, old questions and the meaning of therapies
    Rijntjes, M
    CURRENT OPINION IN NEUROLOGY, 2006, 19 (01) : 76 - 83
  • [38] Is Immunomodulation a Principal Mechanism Underlying How Cell-Based Therapies Enhance Stroke Recovery?
    Satani, Nikunj
    Savitz, Sean I.
    NEUROTHERAPEUTICS, 2016, 13 (04) : 775 - 782
  • [39] Targeting TXNIP for neuroprotection: A novel approach to reducing inflammation and promoting recovery in ischemic stroke
    He, Chongxin
    Bao, Yong
    Xu, Yong
    Cheng, Jingjing
    Hu, Xinxin
    BIOMOLECULES AND BIOMEDICINE, 2024,
  • [40] Targeting TXNIP for neuroprotection: A novel approach to reducing inflammation and promoting recovery in ischemic stroke
    He, Chongxin
    Bao, Yong
    Xu, Yong
    Cheng, Jingjing
    Hu, Xinxin
    BIOMOLECULES AND BIOMEDICINE, 2025, 25 (03): : 553 - 562